Endocrine Abstracts

Hypophosphatasia (HPP) is a rare, inherited, metabolic disorder caused by deficient tissue-nonspecific alkaline phosphatase activity. A heterogeneous presentation in adults includes musculoskeletal symptoms, impaired physical function, and reduced health-related quality of life (HRQoL). Asfotase alfa is the only approved treatment for pediatric-onset HPP. We evaluated, in a real-world setting, the long-term effectiveness of asfotase alfa on physical function and HRQoL among ad...

Background: Hypophosphatasia (HPP) is a rare, inherited metabolic disease caused by deficient activity of tissue nonspecific alkaline phosphatase (TNSALP).Methods: Baseline/pretreatment data from the Global HPP Registry were analyzed to compare HPP disease burden between adults (≥18 years of age) with skeletal manifestations (history of rickets, biopsy-proven osteomalacia, recurrent or poorly healing fractures/pseudofractures, etc; Skeletal group) ...

Background: Survivors with Fontan circulation suffer from chronic systemic hypoperfusion resulting in end-organ injury. Little is known about the effects of these hemodynamic perturbations on bone. We hypothesized that chronic Fontan circulation (>5 years after surgery) would be associated with bone deficits.Methods: Peripheral quantitative computed tomography (pQCT) was performed on 10 Fontan patients (seven males, 11.8±1.7 years) and 11 health...